Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas

Hematol Oncol Clin North Am. 2023 Dec;37(6):1107-1124. doi: 10.1016/j.hoc.2023.05.017. Epub 2023 Jun 23.

Abstract

The authors review the current use of chimeric antigen receptor (CAR)-transduced T cells (CAR-T) in Hodgkin lymphoma (HL) and T-cell lymphomas (TCL) and discuss the data on CD30-targeting CAR-T cells, which seem to be safe and effective in HL. In addition, the authors examine the use of CAR-T cells targeting CD30, CD5, or CD7 in TCL, while highlighting the unique challenges of their use in this subset of lymphomas. Furthermore, the authors present future directions and ongoing trials investigating the use of CAR-T cells in TCL and HL.

Keywords: CD30; CD5; CD7; Chimeric antigen receptor T cells; Hodgkin lymphoma; T-cell non-Hodgkin lymphoma.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Hodgkin Disease* / pathology
  • Hodgkin Disease* / therapy
  • Humans
  • Immunotherapy, Adoptive
  • Ki-1 Antigen
  • Lymphoma*
  • Lymphoma, T-Cell*
  • Receptors, Antigen, T-Cell / genetics
  • Receptors, Chimeric Antigen* / genetics
  • T-Lymphocytes

Substances

  • Receptors, Chimeric Antigen
  • Ki-1 Antigen
  • Receptors, Antigen, T-Cell